Citius Oncology (CTOR) Registration filing summary

Company overview and business model

• Biopharmaceutical company focused on developing and commercializing targeted oncology therapies, with a lead product, LYMPHIR, approved by the FDA in August 2024 for cutaneous T-cell lymphoma (CTCL).

• Business model centers on U.S. commercialization of LYMPHIR and partnering for ex-U.S. markets, leveraging third-party sales and manufacturing partners.

• The company is a majority-owned subsidiary of Citius Pharma, which provides funding and shared services under a formal agreement.

• No current revenue; all funding to date has come from Citius Pharma and external financings.

Financial performance and metrics

• No revenue generated to date; net loss of $21.1 million for the year ended September 30, 2024, and $14.4 million for the six months ended March 31, 2025.

• Accumulated deficit of $53.7 million as of March 31, 2025; cash balance of $112 and negative working capital of $31.7 million.

• Research and development expenses increased to $4.9 million in FY2024 and $4.4 million for the six months ended March 31, 2025, reflecting pre-commercialization activities.

• Outstanding milestone and purchase commitments total over $44 million, including $22.5 million due to Dr. Reddy's and $9.8 million to Eisai.

• Company expects to require substantial additional financing to fund operations and commercialization beyond August 2025.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used primarily for the commercialization of LYMPHIR, milestone and royalty payments under license agreements, working capital, and general corporate purposes.

• If gross proceeds are $10 million or more, the company must repay a $3.8 million promissory note to Citius Pharma.

• Pending use, proceeds will be invested in short-term, investment-grade instruments.